A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods.
Adult
Dipeptides
/ therapeutic use
Heterocyclic Compounds, 1-Ring
/ therapeutic use
Humans
Imaging, Three-Dimensional
Lutetium
/ therapeutic use
Male
Middle Aged
Neoplasms
/ diagnostic imaging
Prostate-Specific Antigen
Radioisotopes
/ therapeutic use
Radiometry
Receptors, Peptide
/ metabolism
Single Photon Emission Computed Tomography Computed Tomography
Journal
Journal of visualized experiments : JoVE
ISSN: 1940-087X
Titre abrégé: J Vis Exp
Pays: United States
ID NLM: 101313252
Informations de publication
Date de publication:
24 04 2020
24 04 2020
Historique:
entrez:
12
5
2020
pubmed:
12
5
2020
medline:
24
9
2020
Statut:
epublish
Résumé
Peptide-receptor-radionuclide-therapy (PPRT) is a targeted therapy that combines a short-range energy radionuclide with a substrate with high specificity for cancer cell receptors. After injection, the radiotracer is distributed throughout the entire body, with a higher uptake in tissues where targeted receptors are overexpressed. The use of beta/gamma radionuclide emitters enables therapy imaging (beta-emission) and post-therapy imaging (gamma-emission) to be performed at the same time. Post-treatment sequential images permit absorbed dose calculation based on local uptake and wash-in/wash-out kinetics. We implemented a hybrid method that combines information derived from both 2D and 3D images. Serial whole-body images and blood samples are acquired to estimate the absorbed dose to different organs at risk and to lesions disseminated throughout the body. A single 3D-SPECT/CT image, limited to the abdominal region, overcomes projection overlap on planar images of different structures such as the intestines and kidneys. The hybrid 2D+3D-SPECT/CT method combines the effective half-life information derived from 2D planar images with the local uptake distribution derived from 3D images. We implemented this methodology to estimate the absorbed dose for patients undergoing PRRT with
Substances chimiques
Dipeptides
0
Heterocyclic Compounds, 1-Ring
0
PSMA-617
0
Radioisotopes
0
Receptors, Peptide
0
Lutetium
5H0DOZ21UJ
Lutetium-177
BRH40Y9V1Q
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Video-Audio Media
Langues
eng
Sous-ensembles de citation
IM